-
Mashup Score: 1
PRESS RELEASE A NEW PUBLICATION IN THE MEDICAL JOURNAL MUSCLE & NERVE VALIDATES THE USE OF THE RATE OF DECLINE OF ALSFRS-R SCORE (ΔFS) FOR THE DESIGN…
Source: www.globenewswire.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 1
LifeMD and Withings Health Solutions partnership exemplifies the potential of digital health technology to transform virtual patient care and improve…
Source: www.globenewswire.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3
This event is supported by Pfizer, Exelixis and Regeneron…
Source: www.globenewswire.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies for HIV Cure - 27 day(s) ago
ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies for HIV Cure …
Source: www.globenewswire.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 3Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) - 1 month(s) ago
MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the…
Source: www.globenewswire.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 2Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation - 1 month(s) ago
GREENWICH, Conn., April 15, 2024 (GLOBE NEWSWIRE) — Regeneron Ventures announces its formation as a venture capital fund focused on promising…
Source: www.globenewswire.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 15Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis - 2 month(s) ago
PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and…
Source: www.globenewswire.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 22Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis - 2 month(s) ago
PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and…
Source: www.globenewswire.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 24
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…
Source: www.globenewswire.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 15
– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – …
Source: www.globenewswire.comCategories: General Medicine News, CardiologistsTweet
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient https://t.co/L1Urhcwl5B